Ken Griffin Pulmonx Corp Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$5.59 - $8.58 $187,265 - $287,430	33,500 New	33,500 $277,000
Q1 2024 May 15, 2024	BUY	$8.71 - $14.65 $3,484 - $5,860	400 Added 50.0%	1,200 $11,000
Q4 2023 Feb 14, 2024	BUY	$7.89 - $13.14 $5,523 - $9,198	700 Added 700.0%	800 $10,000
Q3 2023 Nov 14, 2023	SELL	$9.88 - $14.0 $10,868 - $15,400	-1,100 Reduced 91.67%	100 $1,000
Q2 2023 Aug 14, 2023	BUY	$10.78 - $13.65 $1,078 - $1,365	100 Added 9.09%	1,200 $15,000
Q1 2023 May 15, 2023	BUY	$7.49 - $12.54 $749 - $1,254	100 Added 10.0%	1,100 $12,000
Q4 2022 Feb 14, 2023	SELL	$4.92 - $17.35 $102,828 - $362,615	-20,900 Reduced 95.43%	1,000 $8,000
Q3 2022 Nov 14, 2022	BUY	$15.35 - $23.99 $336,165 - $525,381	21,900 New	21,900 $365,000

124

31M

300

204K

Ticker LUNG
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 37,268,400
Market Cap $235M
Description
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.